Durham-based Pique Therapeutics injects equity & debt cash
Pique Therapeutics, which has a promising immunotherapy treatment for lung cancer, has raised most of a round aimed at just under $1M.
Read Morecancer treatmnt
Durham’s Biomarck Pharmaceuticals launches Phase 2 clinical trial for lung cancer treatment
Posted by Barry Teater | Jan 25, 2018
Durham-based Biomarck Pharmaceuticals has launched a Phase 2 clinical trial of a potential therapy for treating advanced non-small cell lung cancer.
Read More
